Therefore, future studies should also focus on the effects of calcimimetics on adipose tissue inflammation, by treating animals with pharmacological CaSR agonists in different disease conditions like obesity or chronic kidney disease, which could have important clinical implications. This evidence concerns the gene CASR and chronic kidney disease.